Serum thymidine kinase activity in clinically healthy and diseased horses: a potential marker for lymphoma.

The research paper investigates the use of Serum thymidine kinase (sTK) activity in horses as a potential marker for lymphoma, a type of cancer. The findings suggest that horses with lymphoma show significantly higher sTK activity compared to healthy horses and those with non-lymphoma diseases.

Introduction and Research Objective

• The main aim of the study was to evaluate the application of serum thymidine kinase (sTK) as a biomarker for lymphoma in horses. sTK activity, previously used as a prognosis indicator for lymphoma in humans, dogs, and cats, has not been studied extensively in equine medicine.

Research Methodology

• A total of 83 serum samples were collected from different groups of horses – clinically healthy (37), horses with lymphoma (23), horses suffering from non-hematopoietic neoplasia (9), and horses with inflammatory disease (14).
• The activity of sTK in these samples was measured using a radioenzyme assay, a type of biochemical test.
• A reference cut-off value for sTK of less than 2.7 U/L, established based on data from clinically healthy horses, was used to facilitate comparison.

Results and Findings

• The study identified that horses suffering from lymphoma had a significantly higher sTK activity, with an average of 26.3 U/L, ranging from 0.8-443 U/L.
• This was considerably higher than the average values found in horses with non-hematopoietic neoplasia (2.3 U/L) and horses suffering from inflammatory disease (1.5 U/L).
• Lymphoma horses had higher sTK activity than healthy horses, those with inflammatory diseases and horses with non-hematopoietic neoplasia—the differences were statistically significant.

Conclusion

• The research concludes that sTK activity could serve as a useful biomarker for equine lymphoma, based on the significantly higher enzyme activity observed in the lymphoma horse group compared to other tested groups.